142 related articles for article (PubMed ID: 19941110)
1. Towards a standardized protocol for the generation of monocyte-derived dendritic cell vaccines.
Erdmann M; Schuler-Thurner B
Methods Mol Biol; 2010; 595():149-63. PubMed ID: 19941110
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis of monocytes and the influence on yield of monocyte-derived dendritic cells.
Bohnenkamp HR; Burchell JM; Taylor-Papadimitriou J; Noll T
J Immunol Methods; 2004 Nov; 294(1-2):67-80. PubMed ID: 15604017
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cell vaccines in melanoma: from promise to proof?
Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
[TBL] [Abstract][Full Text] [Related]
4. Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients.
Trepiakas R; Pedersen AE; Met O; Hansen MH; Berntsen A; Svane IM
Vaccine; 2008 Jun; 26(23):2824-32. PubMed ID: 18450338
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
6. Optimizing dendritic cell-based immunotherapy for cancer.
Zhong H; Shurin MR; Han B
Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-based immunotherapy.
Osada T; Clay TM; Woo CY; Morse MA; Lyerly HK
Int Rev Immunol; 2006; 25(5-6):377-413. PubMed ID: 17169781
[TBL] [Abstract][Full Text] [Related]
8. Generation of dendritic cell-based vaccines for cancer therapy.
Reinhard G; Märten A; Kiske SM; Feil F; Bieber T; Schmidt-Wolf IG
Br J Cancer; 2002 May; 86(10):1529-33. PubMed ID: 12085199
[TBL] [Abstract][Full Text] [Related]
9. Taming cancer by inducing immunity via dendritic cells.
Palucka AK; Ueno H; Fay JW; Banchereau J
Immunol Rev; 2007 Dec; 220():129-50. PubMed ID: 17979844
[TBL] [Abstract][Full Text] [Related]
10. Human dendritic cell line models for DC differentiation and clinical DC vaccination studies.
Santegoets SJ; van den Eertwegh AJ; van de Loosdrecht AA; Scheper RJ; de Gruijl TD
J Leukoc Biol; 2008 Dec; 84(6):1364-73. PubMed ID: 18664532
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products.
Nicolette CA; Healey D; Tcherepanova I; Whelton P; Monesmith T; Coombs L; Finke LH; Whiteside T; Miesowicz F
Vaccine; 2007 Sep; 25 Suppl 2():B47-60. PubMed ID: 17669561
[TBL] [Abstract][Full Text] [Related]
12. Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy.
Royer PJ; Bougras G; Ebstein F; Leveque L; Tanguy-Royer S; Simon T; Juge-Morineau N; Chevallier P; Harousseau JL; Gregoire M
Exp Hematol; 2008 Mar; 36(3):329-39. PubMed ID: 18207305
[TBL] [Abstract][Full Text] [Related]
13. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
Xia D; Moyana T; Xiang J
Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
[TBL] [Abstract][Full Text] [Related]
14. Cryopreservation of monocytes is superior to cryopreservation of immature or semi-mature dendritic cells for dendritic cell-based immunotherapy.
Hayden H; Friedl J; Dettke M; Sachet M; Hassler M; Dubsky P; Bachleitner-Hofmann T; Gnant M; Stift A
J Immunother; 2009; 32(6):638-54. PubMed ID: 19483645
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells for specific cancer immunotherapy.
Meidenbauer N; Andreesen R; Mackensen A
Biol Chem; 2001 Apr; 382(4):507-20. PubMed ID: 11405216
[TBL] [Abstract][Full Text] [Related]
16. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
17. Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer.
Kao JY; Zhang M; Chen CM; Chen JJ
Immunol Lett; 2005 Nov; 101(2):154-9. PubMed ID: 15993950
[TBL] [Abstract][Full Text] [Related]
18. Phenotype and functional analysis of human monocyte-derived dendritic cells loaded with biodegradable poly(lactide-co-glycolide) microspheres for immunotherapy.
Waeckerle-Men Y; Scandella E; Uetz-Von Allmen E; Ludewig B; Gillessen S; Merkle HP; Gander B; Groettrup M
J Immunol Methods; 2004 Apr; 287(1-2):109-24. PubMed ID: 15099760
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells as vectors for immunotherapy of cancer.
Paczesny S; Ueno H; Fay J; Banchereau J; Palucka AK
Semin Cancer Biol; 2003 Dec; 13(6):439-47. PubMed ID: 15001163
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell immunotherapy for the treatment of neoplastic disease.
Decker WK; Xing D; Shpall EJ
Biol Blood Marrow Transplant; 2006 Feb; 12(2):113-25. PubMed ID: 16443510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
